reduce basal insulin dose when starting glp-1 receptor agonist agonists and beyond. Part 1: benefits in type 2 diabetes RACGP - Appendix 2
Description
#glp1 #diabetes #medication #T2DM | 28 comments on LinkedIn
See if you qualify
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have evolved into multi-organ potential therapeuti...
Background: The evidence on berberine stimulating the secretion of GLP-1 in intestinal L cell has been studied
